Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTLA4Ig/ Abatacept · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CTLA4Ig / Abatacept | DRUG | - |
Inclusion Criteria: * Diagnosis and documentation of a history of stable psoriasis vulgaris of at least 6 months duration. * vulgaris total body surfae area involvement of at least 10% * Failure for toxicity and/or inefficacy of at least one standard anti- psoriatic therapy including topical treatm...
CTLA4Ig/ Abatacept has been studied in psoriasis vulgaris, a chronic inflammatory skin condition. A Phase 2 randomized, double-blind, placebo-controlled trial evaluated the drug in adults with this indication. It is an investigational use for psoriasis and is not established as an approved treatment for this condition.
CTLA4Ig/ Abatacept is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the Phase 2 study of the drug in psoriasis vulgaris.
CTLA4Ig/ Abatacept is in Phase 2 development for psoriasis vulgaris. One Phase 2 trial has been completed, and no active trials are ongoing in this indication. It remains an investigational agent for psoriasis.
CTLA4Ig/ Abatacept was evaluated in a single Phase 2 trial, NCT00287547, titled a Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris. The trial enrolled 144 adults in the United States and is completed.
Yes, CTLA4Ig/ Abatacept is also known as CTLA4Ig. The two names refer to the same drug candidate, which was studied under the code BMS-188667 in a Phase 2 psoriasis vulgaris trial.